Ironwood Pharmaceuticals, Inc.
(NASDAQ: IRWD) today announced it will host its third quarter 2013 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 22, 2013. Individuals interested in participating in the call should dial (877) 643-7155
(U.S. and Canada) or (914) 495-8552 (international) using conference ID number 75229614. To access the webcast, please visit the Investors section of Ironwood’s website at
at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
The call will be available for replay via telephone starting October 22, 2013 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on October 29, 2013. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 75229614. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and science of making medicines, from discovery through commercialization. We’re focused on three goals: transforming knowledge into medicines that make a difference for patients, creating value that will inspire the continued support of our fellow shareholders, and building a team that passionately pursues excellence. Our first product, linaclotide, is approved in the United States and Europe. Our pipeline priorities include exploring further opportunities for linaclotide, leveraging our deep expertise in functional gastrointestinal disorders, and advancing programs in other areas such as allergic conditions, cardiovascular disease, central nervous system disorders and other conditions defined by patient symptoms. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at
or on Twitter at
to learn more about Ironwood. Information that may be important to investors will be routinely posted in both these locations.